25
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Role of TNF–TNF Receptor 2 Signal in Regulatory T Cells and Its Therapeutic Implications

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Tumor necrosis factor α (TNFα) is a pleiotropic cytokine which signals through TNF receptor 1 (TNFR1) and TNF receptor 2 (TNFR2). Emerging evidence has demonstrated that TNFR1 is ubiquitously expressed on almost all cells, while TNFR2 exhibits a limited expression, predominantly on regulatory T cells (Tregs). In addition, the signaling pathway by sTNF via TNFR1 mainly triggers pro-inflammatory pathways, and mTNF binding to TNFR2 usually initiates immune modulation and tissue regeneration. TNFα plays a critical role in upregulation or downregulation of Treg activity. Deficiency in TNFR2 signaling is significant in various autoimmune diseases. An ideal therapeutic strategy for autoimmune diseases would be to selectively block the sTNF/TNFR1 signal through the administration of sTNF inhibitors, or using TNFR1 antagonists while keeping the TNFR2 signaling pathway intact. Another promising strategy would be to rely on TNFR2 agonists which could drive the expansion of Tregs and promote tissue regeneration. Design of these therapeutic strategies targeting the TNFR1 or TNFR2 signaling pathways holds promise for the treatment of diverse inflammatory and degenerative diseases.

          Related collections

          Most cited references114

          • Record: found
          • Abstract: found
          • Article: not found

          Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self.

          Naturally arising CD25(+)CD4(+) regulatory T cells actively maintain immunological self-tolerance. Deficiency in or dysfunction of these cells can be a cause of autoimmune disease. A reduction in their number or function can also elicit tumor immunity, whereas their antigen-specific population expansion can establish transplantation tolerance. They are therefore a good target for designing ways to induce or abrogate immunological tolerance to self and non-self antigens.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            TNF-mediated inflammatory disease.

            JR Bradley (2008)
            TNF was originally described as a circulating factor that can cause necrosis of tumours, but has since been identified as a key regulator of the inflammatory response. This review describes the known signalling pathways and cell biological effects of TNF, and our understanding of the role of TNF in human disease. TNF interacts with two different receptors, designated TNFR1 and TNFR2, which are differentially expressed on cells and tissues and initiate both distinct and overlapping signal transduction pathways. These diverse signalling cascades lead to a range of cellular responses, which include cell death, survival, differentiation, proliferation and migration. Vascular endothelial cells respond to TNF by undergoing a number of pro-inflammatory changes, which increase leukocyte adhesion, transendothelial migration and vascular leak and promote thrombosis. The central role of TNF in inflammation has been demonstrated by the ability of agents that block the action of TNF to treat a range of inflammatory conditions, including rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease and psoriasis. The increased incidence of infection in patients receiving anti-TNF treatment has highlighted the physiological role of TNF in infectious diseases. 2007 Pathological Society of Great Britain and Ireland
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants - past, present and future.

              Tumor Necrosis Factor (TNF), initially known for its tumor cytotoxicity, is a potent mediator of inflammation, as well as many normal physiological functions in homeostasis and health, and anti-microbial immunity. It also appears to have a central role in neurobiology, although this area of TNF biology is only recently emerging. Here, we review the basic biology of TNF and its normal effector functions, and discuss the advantages and disadvantages of therapeutic neutralization of TNF - now a commonplace practice in the treatment of a wide range of human inflammatory diseases. With over ten years of experience, and an emerging range of anti-TNF biologics now available, we also review their modes of action, which appear to be far more complex than had originally been anticipated. Finally, we highlight the current challenges for therapeutic intervention of TNF: (i) to discover and produce orally delivered small molecule TNF-inhibitors, (ii) to specifically target selected TNF producing cells or individual (diseased) tissue targets, and (iii) to pre-identify anti-TNF treatment responders. Although the future looks bright, the therapeutic modulation of TNF now moves into the era of personalized medicine with society's challenging expectations of durable treatment success and of achieving long-term disease remission.
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Immunol
                Front Immunol
                Front. Immunol.
                Frontiers in Immunology
                Frontiers Media S.A.
                1664-3224
                19 April 2018
                2018
                : 9
                : 784
                Affiliations
                [1] 1Department of Clinical Immunology, Third Hospital at Sun Yat-sen University , Guangzhou, China
                [2] 2Division of Rheumatology, Milton S. Hershey Medical Center at Penn State University , Hershey, PA, United States
                [3] 3Research Service, Memphis VA Medical Center , Memphis, TN, United States
                Author notes

                Edited by: Xin Chen, University of Macau, Macau

                Reviewed by: Baojun Zhang, Duke University, United States; Ye Zheng, Salk Institute for Biological Studies, United States; Girdhari Lal, National Centre for Cell Science, India

                *Correspondence: Song Guo Zheng, szheng1@ 123456pennstatehealth.psu.edu

                These authors have contributed equally to this work.

                Specialty section: This article was submitted to Immunological Tolerance and Regulation, a section of the journal Frontiers in Immunology

                Article
                10.3389/fimmu.2018.00784
                5916970
                29725328
                9ffe55c6-7fcd-46da-8315-628c931c8903
                Copyright © 2018 Yang, Wang, Brand and Zheng.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 04 February 2018
                : 28 March 2018
                Page count
                Figures: 2, Tables: 0, Equations: 0, References: 143, Pages: 11, Words: 9978
                Funding
                Funded by: National Institute of Arthritis and Musculoskeletal and Skin Diseases 10.13039/100000069
                Funded by: National Key R&D Program of China
                Award ID: 2017YFA0105800
                Funded by: National Natural Science Foundation of China 10.13039/501100001809
                Award ID: 81671611
                Funded by: Guangdong Innovative and Entrepreneurial Research Team Program 10.13039/100012541
                Award ID: 2016ZT06S252
                Funded by: National Institutes of Health 10.13039/100000002
                Award ID: AR059103 and AR073409
                Categories
                Immunology
                Review

                Immunology
                tumor necrosis factor α,tumor necrosis factor receptor 1,tumor necrosis factor receptor 2,regulatory t cells,autoimmune diseases

                Comments

                Comment on this article